Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet for K/DOQI Targets in ESRD
NCT00110890Phase 4Completed
- Sponsor
- Amgen
- Start
- May 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial in secondary hyperparathyroidism (SHPT) comparing Cinacalcet with Standard of Care (2 arms). Primary endpoint: Number of Participants With Mean PTH <= 300 pg/mL. Started May 2004; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00110890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110890.